Exploration of Medicine

Open Exploration

Open Access Correction

Correction: Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges

Yoshiharu Sato*

DNA Chip Research Inc., Kawasaki 3-1200, Japan

***Correspondence:** Yoshiharu Sato, DNA Chip Research Inc., Shinmaruko-Higashi, Nakahara-ku, Kawasaki 3-1200, Japan. yo-sato@dna-chip.co.jp

Published: September 19, 2025

Cite this article: Sato Y. Correction: Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges. Explor Med. 2025;6:1001358. https://doi.org/10.37349/emed.2025.1001358

Correction to “Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges” by Sato Y. Explor Med. 2025;6:1001349. DOI: 10.37349/emed.2025.1001349

In the recently published review article, an error was identified in the description of the BR.31 trial (in the section “Ongoing prospective NSCLC MRD studies”). The article incorrectly stated that “The BR.31 trial (NCT02273375) is evaluating the efficacy of atezolizumab (anti-PD-L1) compared to placebo in patients with stage IB–IIIA NSCLC following surgical resection”. The correct statement is that “The BR.31 trial (NCT02273375) is evaluating the efficacy of durvalumab (anti-PD-L1) compared to placebo in patients with stage IB–IIIA NSCLC following surgical resection”. The author sincerely apologizes for this error and any confusion it may have caused to readers and the research community. This has now been amended in the HTML and PDF versions of the article.

The original uncorrected PDF can be accessed from https://www.explorationpub.com/uploads/er1001349.pdf